SURVYR

IOVA

Iovance Biotherapeutics, Inc.
$15.05
+$0.19 (1.28%)Oct 21 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-24%+123%+269%+416%+563%Oct 2025Oct 2026Apr 202652w high $15.3752w low $1.76
IOVASPY
Wall St. Highest PT $20.00 (+32.9%) Wall St. Avg PT $14.40 (-4.3%)
$2$7$11$16$21POC $4Hi $20Avg $14
Underwater Drawdown %Max DD -39.0%Current 0.0%
0.0%-39.0%
Relative Strength vs SPY+532.3% vs SPYOutperforming
+612%0%-612%
1W
+$0.84 (5.91%)
1M
+$4.86 (47.69%)
3M
+$9.88 (191.10%)
6M
+$11.52 (326.35%)
YTD
+$12.32 (451.28%)
1Y
+$12.78 (563.00%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
10 analysts · mean score 1.60
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$15.05
Average target$14.40
−$0.65 (−4.3%) downsideaverage target vs current price
CurrentAverageMedian
Low$7.00
Median$14.40
High$20.00
12-month Wall Street target range
Recent analyst rating changes · 30
Reiterated
2026-10-13 · Barclays reiterated Overweight on IOVA
Reiterated
2026-10-08 · Baird reiterated Neutral on IOVA
Reiterated
2026-09-30 · Wells Fargo reiterated Overweight on IOVA
Reiterated
2026-09-29 · HC Wainwright & Co. reiterated Buy on IOVA
Reiterated
2026-09-17 · Barclays reiterated Overweight on IOVA
Reiterated
2026-08-25 · TD Cowen reiterated Buy on IOVA
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$6.4B
P/E (next 12 months, estimated)-72.0
52-week range$1.76 – $15.37
Revenue growth (latest quarter vs a year ago)+65.7%
Dividend yieldNo dividend
Analyst consensusBuy (10)
Average analyst price target$14.40 (-4%)

What they do

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for IOVA yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
ranked 4 of 589 · 12-month momentum 266.4%
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

IOVA earningsNext report in 8 days
Next report · quarter Sep 2026
Thu Nov 5, 2026Before the open
EPS consensus-$0.09 range -$0.10–-$0.07
Revenue consensus$115.0M 7 analysts
Last 4 quarters · EPS vs estimate
Aug 6, 2026-$0.11est -$0.13+18.4%Above estimates
May 7, 2026-$0.19est -$0.15−23.8%Below estimates
Feb 24, 2026-$0.18est -$0.18−2.0%In line with estimates
Nov 6, 2025-$0.25est -$0.26+2.9%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-24 14:43:02 ET
24-1125-0225-0525-0825-1126-0226-0526-08-0.360.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$99.3M+65.7%
2026-03-31$71.4M–
2025-12-31$86.8M–
2025-09-30$67.5M–
2025-06-30$60.0M–

News & catalysts

More news
Iovance’s Melanoma Therapy Shows Promising 4-Year Data – Retail Says Acquisition Imminent Before 2027-End
Stocktwits · Oct 23
Iovance Biotherapeutics Reports 62.5% Overall Response Rate in Phase 2 Melanoma Trial
MT Newswires · Oct 23
Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced Melanoma
GlobeNewswire · Oct 23
Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026
GlobeNewswire · Oct 19
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire · Oct 16
Rating changes
Reiterated
2026-10-13 · Barclays reiterated Overweight on IOVA
Reiterated
2026-10-08 · Baird reiterated Neutral on IOVA
Reiterated
2026-09-30 · Wells Fargo reiterated Overweight on IOVA
Reiterated
2026-09-29 · HC Wainwright & Co. reiterated Buy on IOVA
Reiterated
2026-09-17 · Barclays reiterated Overweight on IOVA
Reiterated
2026-08-25 · TD Cowen reiterated Buy on IOVA

Third-party analyst actions, not SURVYR.'s views. All rating changes

Stats refreshed 2026-10-24 14:43:02 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026